Director, Global Medical Affairs - GI Oncology

About the role

The Director, Global Medical Affairs will report to the GI Tumors Medical Affairs Strategy Lead and will be responsible for supporting the development and execution of the Global Medical Affairs (GMA) strategy and tactical plans for Revolution Medicines assets being developed for the treatment of GI cancers, with a focus on PDAC and CRC. Key aspects of this role include the following: support the development and execution of a Healthcare Professional (HCP) engagement strategy to gather insights that shape internal programs; act as the medical representative on cross-functional teams; serve as a therapeutic area content expert; and support medical affairs functions as needed. As a member of the GMA team, the successful candidate will participate in the Global Medical Affairs Team (GMAT) to execute medical strategies, contribute to the operations and oversight of medical activities, and work cross-functionally to support associated pre-launch activities. This role is an essential member of the Medical Affairs team who will work as an extension of the GMA organization, collaborating with stakeholders across the organization, including, but not limited to, Clinical Development and Operations, Commercial Operations, Program Management, Business Development, Regulatory, Safety, and Compliance teams. The ideal candidate is an effective communicator, entrepreneurial, detail-oriented, proactive, scientifically driven, a skilled collaborator, and able to build compelling scientific narratives and effectively implement medical tactics aligned with the Medical Affairs plans.

Responsibilities

• Lead the development and execution of the GMA strategy and medical objectives as part launch readiness/launch execution, including activities related to scientific engagement and communication, evidence generation, internal education, and patient advocacy.
• Coordinates the execution of routine gap assessments leading to the development and refinement of a publication strategy, evidence generation plan, and tactical plan as part of the overall GMA plan.
• Communicates clinical and scientific data to KOLs and other healthcare professionals through presentations, educational programs, and scientific discussions.
• Represents medical affairs functions in cross-functional strategy team meetings, including Clinical and Safety sub-teams, Global Brand Team, Global Product Team, Patient Advocacy, Market Access, and other cross-functional strategic discussions.
• Participates in the Global Medical Affairs Team (GMAT) to execute medical strategies, contribute to the operations and oversight of medical activities, and work cross-functionally to support associated pre-launch activities.
• Partners with RWE strategy and Biomarker/CDx teams on integrated evidence generation strategies and activities as part of the GMA Plan.
• Works with the Patient Advocacy and Grants teams to incorporate the patient voice and define external medical education strategies for independent grants.
• Provides medical support for scientific symposia and medical congresses and collaborate across GMA functions to develop, review, and align on key scientific communication points and medical information response documents within legal and compliance guidelines.
• Supports the review and approval of abstracts, manuscripts, corporate communications, and other data disclosure documents as well as internal stakeholder medical education activities related to the compound data and related competitor data.
• Required Skills, Experience and Education:
• An advanced doctorate degree (PharmD, PhD, MD, DO or equivalent) in medical or scientific area is required.
• 7+ years of relevant experience in Medical Affairs within the biotech and/or pharmaceutical industry ( local, regional, and global levels) and/or prior clinical oncology practice.
• Strong scientific background in oncology, with preferred experience in GI c

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience